loading
Lyell Immunopharma Inc stock is traded at $13.70, with a volume of 91,646. It is down -1.40% in the last 24 hours and up +3.27% over the past month. Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
See More
Previous Close:
$13.95
Open:
$13.86
24h Volume:
91,646
Relative Volume:
0.52
Market Cap:
$334.74M
Revenue:
$31,000
Net Income/Loss:
$-246.41M
P/E Ratio:
-1.0752
EPS:
-12.7377
Net Cash Flow:
$-134.42M
1W Performance:
-4.01%
1M Performance:
+3.27%
6M Performance:
-45.80%
1Y Performance:
+30.01%
1-Day Range:
Value
$13.39
$13.93
1-Week Range:
Value
$13.39
$15.52
52-Week Range:
Value
$10.49
$45.00

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name
Name
Lyell Immunopharma Inc
Name
Phone
650 695-0677
Name
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Employee
161
Name
Twitter
Name
Next Earnings Date
2026-08-11
Name
Latest SEC Filings
Name
LYEL's Discussions on Twitter

Compare LYEL vs VRTX, REGN, ARGX, RVMD, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
LYEL icon
LYEL
Lyell Immunopharma Inc
13.66 341.85M 31,000 -246.41M -134.42M -12.74
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
515.63 128.19B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
807.01 82.72B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
991.71 53.26B 4.16B 1.29B 734.26M 19.58
RVMD icon
RVMD
Revolution Medicines Inc
213.05 43.66B 742.00K -1.37B -1.07B -7.0731
ONC icon
ONC
Beone Medicines Ltd Adr
362.46 39.31B 5.76B 514.49M 1.10B 4.4813

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-10-26 Initiated Needham Buy
Mar-09-26 Initiated Citizens Mkt Outperform
Dec-09-25 Upgrade H.C. Wainwright Neutral → Buy
Oct-30-24 Downgrade BofA Securities Buy → Underperform
Jun-27-24 Downgrade H.C. Wainwright Buy → Neutral
Aug-28-23 Downgrade JP Morgan Overweight → Neutral
Nov-14-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-11-22 Downgrade Goldman Buy → Neutral
Oct-17-22 Initiated H.C. Wainwright Buy
Jul-12-21 Initiated BofA Securities Buy
Jul-12-21 Initiated Goldman Buy
Jul-12-21 Initiated JP Morgan Overweight
Jul-12-21 Initiated Morgan Stanley Overweight
View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

pulisher
Aug 14, 2026

Lyell Immunopharma (LYEL): Foresite funds and Tananbaum report 2.7% ownership - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Citizens reiterates Lyell Immunopharma stock rating on pipeline progress By Investing.com - Investing.com Canada

Aug 14, 2026
pulisher
Aug 13, 2026

Lyell Immunopharma, Inc. (NASDAQ:LYEL) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Aug 13, 2026
pulisher
Aug 11, 2026

Lyell Immunopharma VP Bulis sells $8,905 of common stock By Investing.com - Investing.com Nigeria

Aug 11, 2026
pulisher
Aug 11, 2026

Lyell Immunopharma VP Veronica Sanchez Bulis Sells 621 Shares for Tax Withholding on August 10, 2026 - Kalkine Media

Aug 11, 2026
pulisher
Aug 11, 2026

Lyell Immunopharma COO Stephen J. Hill Sells Shares to Cover Tax Withholding on RSU Settlement - Kalkine Media

Aug 11, 2026
pulisher
Aug 11, 2026

Lyell Immunopharma (LYEL) CSO auto-sells shares to cover RSU tax withholding - Stock Titan

Aug 11, 2026
pulisher
Aug 11, 2026

Lyell Immunopharma VP Bulis sells $8,905 of common stock - Investing.com

Aug 11, 2026
pulisher
Aug 11, 2026

Lyell Immunopharma (LYEL) VP auto-sells 621 shares to cover RSU taxes - Stock Titan

Aug 11, 2026
pulisher
Aug 11, 2026

Lyell Immunopharma (LYEL) COO auto-sells 89 shares for RSU tax withholding - Stock Titan

Aug 11, 2026
pulisher
Aug 11, 2026

Lyell Immunopharma (LYEL) CEO sells shares to cover RSU tax withholding - Stock Titan

Aug 11, 2026
pulisher
Aug 11, 2026

Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat

Aug 11, 2026
pulisher
Aug 10, 2026

Lyell Immunopharma, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 10, 2026
pulisher
Aug 09, 2026

Lyell Immunopharma earnings beat by $0.22, revenue fell short of estimates - Investing.com Canada

Aug 09, 2026
pulisher
Aug 08, 2026

Possible Signal As Lyell Immunopharma Insiders Sell US$527k In Stock - webull.com

Aug 08, 2026
pulisher
Aug 08, 2026

Lyell Immunopharma (NASDAQ:LYEL) Posts Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat

Aug 08, 2026
pulisher
Aug 07, 2026

Lyell Immunopharma, Inc. expected to post a loss of $2.08 a shareEarnings Preview - TradingView

Aug 07, 2026
pulisher
Aug 06, 2026

Lyell Immunopharma: Q2 Earnings Snapshot - AOL.com

Aug 06, 2026
pulisher
Aug 06, 2026

Lyell Immunopharma reports Q2 2026 net loss $44.8M, cash $228.0M; clinical milestones advance - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026 - manilatimes.net

Aug 06, 2026
pulisher
Aug 06, 2026

BRIEF-Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million - TradingView

Aug 06, 2026
pulisher
Aug 06, 2026

This Lyell Immunopharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - benzinga.com

Aug 06, 2026
pulisher
Aug 06, 2026

Lyell Immunopharma (NASDAQ:LYEL) Earns Buy Rating from Analysts at Stifel Nicolaus - MarketBeat

Aug 06, 2026
pulisher
Aug 06, 2026

Stifel Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $36 - Moomoo

Aug 06, 2026
pulisher
Aug 06, 2026

Lyell Immunopharma (LYEL) Earnings Date and Reports 2026 $LYEL - MarketBeat

Aug 06, 2026
pulisher
Aug 05, 2026

LYELL IMMUNOPHARMA, INC. : STIFEL INITIATES COVERAGE WITH BUY RATING; TARGET PRICE $36 - Bitget

Aug 05, 2026
pulisher
Aug 05, 2026

Stifel initiates Lyell Immunopharma stock with buy rating on CAR T therapy - Investing.com South Africa

Aug 05, 2026
pulisher
Aug 05, 2026

LYEL Q2'26 Earnings: revenue estimate is 4.60K USD - TradingView

Aug 05, 2026
pulisher
Aug 04, 2026

Lyell Immunopharma (LYEL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat

Aug 04, 2026
pulisher
Jul 29, 2026

Price to book forward of Lyell Immunopharma, Inc. – NASDAQ:LYEL - TradingView

Jul 29, 2026
pulisher
Jul 27, 2026

Form 4 Lyell Immunopharma Inc For: 27 July By Investing.com - Investing.com Nigeria

Jul 27, 2026
pulisher
Jul 27, 2026

Lyell Immunopharma, Inc. (LYEL) holder pays broker with 44,000 shares - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

Broker commission transfer of 38,500 shares in Lyell Immunopharma (LYEL) - Stock Titan

Jul 27, 2026
pulisher
Jul 27, 2026

Lyell Immunopharma Inc (LYEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Lyell Immunopharma Inc (LYEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026
pulisher
Jul 27, 2026

Lyell Immunopharma Inc (LYEL) Cash Flow - TradingKey

Jul 27, 2026
pulisher
Jul 25, 2026

Lyell Immunopharma Inc (LYEL) Institutional Confidence - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

Lyell Immunopharma Inc (LYEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jul 25, 2026
pulisher
Jul 25, 2026

LYEL|Lyell Immunopharma Inc|Price:12.950|Chg%:+0.320 - TradingKey

Jul 25, 2026
pulisher
Jul 24, 2026

TradingKey - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Lyell Immunopharma Inc (LYEL) Balance Sheet - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

LYEL|Lyell Immunopharma Inc|Price:12.615|Chg%:-0.165 - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Lyell Immunopharma, Inc. Revenue Breakdown – NASDAQ:LYEL - TradingView

Jul 24, 2026
pulisher
Jul 24, 2026

Lyell Immunopharma Inc (LYEL) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 24, 2026
pulisher
Jul 24, 2026

Lyell Immunopharma Inc (LYEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026
pulisher
Jul 22, 2026

B. Riley Securities Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $44 - Moomoo

Jul 22, 2026
pulisher
Jul 22, 2026

LYEL Initiates Coverage by B. Riley Securities -- Price Target A - GuruFocus

Jul 22, 2026
pulisher
Jul 22, 2026

Stifel initiates Lyell Immunopharma stock with buy, $44 target - Investing.com India

Jul 22, 2026
pulisher
Jul 22, 2026

Lyell Immunopharma, Inc. SEC Filing (Jul 22, 2026) - Stock Titan

Jul 22, 2026
pulisher
Jul 22, 2026

Stifel initiates Lyell Immunopharma stock with buy, $44 target By Investing.com - Investing.com Canada

Jul 22, 2026
pulisher
Jul 21, 2026

Form 4 Lyell Immunopharma Inc For: 21 July By Investing.com - Investing.com Nigeria

Jul 21, 2026

Lyell Immunopharma Inc Stock (LYEL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Lyell Immunopharma Inc Stock (LYEL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Lee Gary K.
Chief Scientific Officer
Aug 10 '26
Sale
14.34
131
1,879
17,677
Hill Stephen J.
Chief Operating Officer
Aug 10 '26
Sale
14.34
89
1,276
17,805
Seely Lynn
President and CEO
Aug 10 '26
Sale
14.34
390
5,593
73,488
Innovative Cellular Therapeuti
10% Owner
Jul 17 '26
Sale
13.70
10
137
2,857,480
Innovative Cellular Therapeuti
10% Owner
Jul 16 '26
Sale
13.73
10
137
2,857,490
Seely Lynn
President and CEO
May 11 '26
Sale
18.91
388
7,337
73,878
Lee Gary K.
Chief Scientific Officer
May 11 '26
Sale
18.92
130
2,460
17,808
Hill Stephen J.
Chief Operating Officer
May 11 '26
Sale
18.92
89
1,684
17,894
Bulis Veronica Sanchez
VP, Corporate Controller
May 11 '26
Sale
18.91
217
4,103
15,420
Shook David
Chief Medical Officer
Jun 10 '26
Sale
12.64
1,977
24,989
20,923
$64.75
price up icon 2.24%
$36.34
price up icon 0.33%
$59.21
price up icon 0.99%
$127.69
price up icon 3.10%
$224.88
price down icon 1.78%
ONC ONC
$361.87
price up icon 3.91%
Cap:     |  Volume (24h):